Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors.
Rueeger, H., Rondeau, J.M., McCarthy, C., Mobitz, H., Tintelnot-Blomley, M., Neumann, U., Desrayaud, S.(2011) Bioorg Med Chem Lett 21: 1942-1947
- PubMed: 21388807 
- DOI: https://doi.org/10.1016/j.bmcl.2011.02.038
- Primary Citation of Related Structures:  
3PI5, 3QBH - PubMed Abstract: 
This Letter describes the de novo design of non-peptidic hydroxyethylamine (HEA) inhibitors of BACE-1 by elimination of P-gp contributing amide attachments. The predicted binding mode of the novel cyclic sulfone HEA core template was confirmed in a X-ray co-crystal structure. Inhibitors of sub-micromolar potency with an improved property profile over historic HEA inhibitors resulting in improved brain penetration are described.
Organizational Affiliation: 
Novartis Institutes for BioMedical Research, Novartis Pharma AG, PO Box, CH-4002 Basel, Switzerland. heinrich.rueeger@novartis.com